<SEC-DOCUMENT>0001171843-24-001185.txt : 20240305
<SEC-HEADER>0001171843-24-001185.hdr.sgml : 20240305
<ACCEPTANCE-DATETIME>20240305082902
ACCESSION NUMBER:		0001171843-24-001185
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240305
FILED AS OF DATE:		20240305
DATE AS OF CHANGE:		20240305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVO NORDISK A S
		CENTRAL INDEX KEY:			0000353278
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-82318
		FILM NUMBER:		24718386

	BUSINESS ADDRESS:	
		STREET 1:		NOVO ALLE DK 2880
		CITY:			BAGSVAERD DENMARK
		STATE:			G7
		ZIP:			00000
		BUSINESS PHONE:		4544448888

	MAIL ADDRESS:	
		STREET 1:		NOVO ALLE DK 2880
		CITY:			BAGSVAERD DENMARK
		STATE:			G7
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVO NORDISK A/S
		DATE OF NAME CHANGE:	19900807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVO INDUSTRI A S /DENMARK/
		DATE OF NAME CHANGE:	19890811
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_030524.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>UNITED STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Washington, D.C. 20549</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>________________</I></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>FORM 6-K</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>________________</I></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">of the Securities Exchange Act of 1934</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> March 5, 2024</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>________________</I></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>NOVO NORDISK A/S</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<FONT STYLE="font-size: 10pt">(Exact name
of Registrant as specified in its charter)</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Novo All&eacute; 1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>DK- 2880, Bagsvaerd</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Denmark</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Address of principal executive offices)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>________________</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: right"><font style="font-size: 10pt">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></td>
    <td style="width: 50%; font-size: 10pt"><font style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</font></td></tr>
</table>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 12pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: right">&nbsp;<IMG SRC="logo.jpg" ALT="" STYLE="height: 70px; width: 97px"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="ca.jpg" ALT="" STYLE="height: 80px; width: 387px">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 14pt"><B>Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial</B></FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B></B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="margin: 0pt; font-size: 10pt"><B>Bagsv&aelig;rd, Denmark, 5 March 2024</B> &ndash; Novo Nordisk today announced
the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to
efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data Monitoring Committee. The double-blind
trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment
and risk of kidney and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease (CKD). The trial enrolled 3,533
people with type 2 diabetes and CKD.</P>

<P STYLE="font-size: 10pt; margin: 0pt 6.5pt 0pt 7.95pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt"></P>

<P STYLE="margin: 0pt; font-size: 10pt">The trial achieved its primary endpoint by demonstrating a statistically significant and
superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people treated with
semaglutide 1.0 mg compared to placebo<SUP>1</SUP>. The combined primary endpoint included five components measuring the progression
of CKD and the risk of kidney and cardiovascular mortality. Both CKD and cardiovascular components of the primary endpoint
contributed to the risk reduction. Further, superiority of semaglutide 1 mg vs placebo was confirmed for the confirmatory secondary
endpoints.</P>

<P STYLE="font-size: 10pt; margin: 0pt 6.5pt 0pt 7.95pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt">In the trial, semaglutide 1.0 mg appeared to have a safe and well-tolerated
profile in line with previous semaglutide 1.0 mg trials.</P>

<P STYLE="font-size: 10pt; margin: 0pt 12.4pt 0pt 7.95pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt">&quot;We are very excited about the results from FLOW showing that semaglutide
1.0 mg reduces the risk of kidney disease progression,&rdquo; said Martin Holst Lange, executive vice president for Development at Novo
Nordisk. &ldquo;Approximately 40% of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate
the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6.5pt 0pt 7.95pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>






<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.15pt 0pt 0; text-align: right; color: #82786F">Page 2 of 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.15pt 0pt 0; text-align: left; color: #82786F">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt">Novo Nordisk expects to file for regulatory
approvals of a label expansion for Ozempic<FONT STYLE="font-size: 10pt">&reg;</FONT> in the US and EU in 2024. The detailed results from
FLOW will be presented at a scientific conference in 2024.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.05pt; margin: 0pt 15.45pt 0pt 8pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt"><B>About FLOW</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 8pt"></P>

<P STYLE="margin: 0pt; font-size: 10pt">FLOW was a randomised, double-blind, parallel-group, placebo-controlled, superiority trial comparing
injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care on kidney outcomes for prevention of progression of kidney
impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and CKD (defined as eGFR<FONT STYLE="font-size: 10pt"><SUP>2
</SUP></FONT>&ge;50 and &le;75mL/min/1.73 m2 and UACR &gt;300 and &lt;5000 mg/g or eGFR &ge;25 and &lt;50 mL/min/1.73 m2 and UACR &gt;100
and &lt;5000 mg/g). 3,533 people were enrolled in the trial conducted in 28 countries at around 400 investigator sites. The FLOW trial
was initiated in 2019.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt">The key objective of the FLOW trial is to demonstrate delay in progression of CKD and to lower
the risk of kidney and cardiovascular mortality through the composite primary endpoint consisting of the following five components: onset
of persistent &ge; 50% reduction in eGFR according to the CKD-EPI<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT> equation compared
with baseline, onset of persistent eGFR (CKD-EPI) &lt; 15 mL/min/1.73 m2, initiation of chronic kidney replacement therapy (dialysis
or kidney transplantation), death from kidney disease or death from cardiovascular disease. Confirmatory secondary endpoints include
annual rate of change in eGFR<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT> (CKD-EPI), MACE (non-fatal myocardial infarction, non-fatal
stroke, cardiovascular death) and all-cause death.</P>

<P STYLE="font-size: 10pt; margin: 0pt 12.4pt 0pt 7.95pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt"><B>About Ozempic<FONT STYLE="font-size: 10pt">&reg;</FONT></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 7.95pt"></P>

<P STYLE="margin: 0pt; font-size: 10pt">Once-weekly subcutaneous semaglutide is approved in 0.5 mg, 1.0 mg and 2.0 mg
doses under the brand name Ozempic<FONT STYLE="font-size: 10pt">&reg;</FONT> and indicated as an adjunct to diet and exercise to improve
glycaemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes
and established cardiovascular disease.</P>

<P STYLE="font-size: 10pt; margin: 0pt 9.35pt 0pt 7.95pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt"><I>Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs
about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit <FONT STYLE="color: Black">novonordisk.com,
Facebook, Instagram, X, LinkedIn and YouTube.</FONT></I></P>

<P STYLE="font-size: 10pt; margin: 0pt 5.95pt 0pt 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.15pt 0pt 0; text-align: left; color: #82786F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.15pt 0pt 0; text-align: left; color: #82786F"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.15pt 0pt 0; text-align: right; color: #82786F"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.15pt 0pt 0; text-align: right; color: #82786F"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.15pt 0pt 0; text-align: right; color: #82786F"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.15pt 0pt 0; text-align: right; color: #82786F">Page 3  of 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6.3pt 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="margin: 0pt; font-size: 10pt"><B>Contacts for further information</B></P>

<P STYLE="font-size: 10pt; margin: 4.2pt 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: Black"><B>Media:</B></FONT></TD>
    <TD STYLE="width: 49%; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Ambre James-Brown</B></FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">+45 3079 9289</FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">abmo@novonordisk.com</FONT></P></TD>
    <TD><P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Liz Skrbkova (US)</B></FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">+1 609 917 0632</FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">lzsk@novonordisk.com</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: Black"><B>Investors:</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Daniel Muusmann Bohsen</B></FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">+45 3075 2175</FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">dabo@novonordisk.com</FONT></P></TD>
    <TD><P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Jacob Martin Wiborg Rode</B></FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">+45 3075 5956</FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">jrde@novonordisk.com</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B>David Heiberg Landsted</B></FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">+45 3077 6915</FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">dhel@novonordisk.com</FONT></P></TD>
    <TD><P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Mark Joseph Root (US)</B></FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">+1 848 213 3219</FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">mjhr@novonordisk.com</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Sina Meyer</B></FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">+45 3079 6656</FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">azey@novonordisk.com</FONT></P></TD>
    <TD><P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Frederik Taylor Pitter</B></FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">+45 3075 8259</FONT></P>
    <P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="color: Black">fptr@novonordisk.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 4.65pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 7.65pt"><FONT STYLE="font-size: 8pt">1.</FONT></TD><TD><FONT STYLE="font-size: 8pt">Based on treatment policy estimand: treatment
                                            effect regardless of treatment adherence</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 7.65pt"><FONT STYLE="font-size: 8pt">2.</FONT></TD><TD><FONT STYLE="font-size: 8pt">eGFR: estimated glomerular filtration
                                            rate</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 7.65pt"><FONT STYLE="font-size: 8pt">3.</FONT></TD><TD><FONT STYLE="font-size: 8pt">CKD-EPI: Chronic Kidney Disease Epidemiology
                                            Collaboration</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><TABLE CELLSPACING="0" CELLPADDING="3" STYLE="width: 100%; font-size: 10pt">
<tr style="vertical-align: top"><TD STYLE="width: 25%"><P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>Novo Nordisk A/S</B></FONT></P><P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Investor Relations</FONT></P></td><TD STYLE="width: 25%"><P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Novo Alle 1</FONT></P><P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">2880 Bagsv&aelig;rd</FONT></P><P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Denmark</FONT></P></td><TD STYLE="width: 25%"><P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Telephone:</FONT></P><P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">+45 4444 8888</FONT></P></td><TD STYLE="width: 25%"><P STYLE="font-size: 10pt; margin: 0pt 0"></P><P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Internet:<BR>
www.novonordisk.com</FONT><BR> <FONT STYLE="font-size: 8pt">CVR no: <BR>
24 25 67 90</FONT></P></td></tr>
<tr><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Company
announcement No 20  / 2024</FONT></TD></tr>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>



<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURES</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 29%"><FONT STYLE="font-size: 10pt">Date: March 5, 2024</FONT></td>
    <td style="width: 71%">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">NOVO NORDISK A/S</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><u>Lars Fruergaard J&oslash;rgensen</u></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Chief Executive Officer</P></td></tr>
</table>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @$ QP#'  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
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M6_MD$=P(M/MFC$JK(%)2W&1N!P>:+^UMM+^*>B_V=&MJM[8W N4A C23:DS
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M67*=<YP#0!1^&^EV6KZ--XAUB"*]OM3NYVEEG192%4[ @W X7@\#^@K)F/\
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IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ca.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ca.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !Z DL# 2(  A$! Q$!_\0
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M"*2?EW9923Z_0'[07[0WA?\ 9S\%MKWB*5IIYB8['3+<CS[R3^ZH/0#(+,>
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MH3Z;=-"9'E.(XVVD?=5"W_;05\<V_P"TG\7KJXB@A^(WBF261@B(NJ399B<
M#YO6J?[0WQ,F^,'QJ\7>*Y9!)#?7[BUQT6V3]W"/^_:IGU.3WKTO]@'X3'XI
M_M':%)<6PGTGP^#K-WN'RYC(\E3ZDRE..X5O0U][1H4<#@DZD5>*N_7_ (<^
M3J5JF*Q34).S=EZ'ZW?!_P ,ZIX-^&'AG1]<U2ZUK6[:QC%]?WDK2R2W!&Z0
M[FYP&) ST  KL***_,Y2<Y.3ZGV\5RI)!1114C"BBB@ HHHH **** "BBB@
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M>VCWM^I^KO\ P2IU22\_9_UNU=B4L_$$R(#V#0PL<?B37QM_P46_Y.Z\9_\
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M_P %&_\ D[?Q;_U[V/\ Z215Y_\ LF_\G,?#+_L/6G_HP5^@4?\ D71_P?\
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M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=Q&A^S6((P1"&&2QY'F$ X. !SF:N,PF64?9TFFULEK]XZ>%Q..J\]167?\
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M7?\ OP/\:]7(:U.GAI*<DGS=7Y(X,VI5)UHN,6].WFS]%/\ @F#_ ,FP1_\
M89N_Y1U]:U\U?\$^_A]XC^&?[/L>C>*='NM#U0:K<S?9;M=K[&V;6QZ'!KZ5
MKY3,)*6+J.+NKL^APJ<:$$^R/QJ_X*-_\G;^+?\ KWL?_22*O/\ ]DW_ ).8
M^&7_ &'K3_T8*^B?VZ/V;OB=\1/VEO$NN^&_!6JZSH]Q#9K%>6L0:-RMM&K
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MC5F)_P!DU^.%?T2:GIMKK6FW>GWL"W-E=PO!/#(,K)&RE64^Q!(K\G/VCO\
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M[E7DCS\L\).)(F]59<C\<CD"OWRL+R/4K&WNX3NAGC65&]58 C]#7\[-?O\
M_!\D_"7P23R?[#L?_2=*Y.(J<?W=3KJCHR6;M.'30_'#]MW_ ).L^(W_ &$%
M_P#1,=>/6.OZEI>FZEI]I>S6]EJ2)'>6\;D).J.'0..^&4$>XKV']MW_ ).L
M^(W_ &$%_P#1,=<C^SWX!7XH?&[P3X7EC\ZUU#5(4N4]8%;?-_Y#5Z^FP\HP
MPD)2V44_N1X=2+EB)1CNVU][/2/A)^P1\6OC%X9M?$.G:=8Z/I%XOF6MQK-R
M83.G9U159MI[$@ CD9'-<U\>/V2?B)^SK;6E[XIL+:72KJ3R8]2TV?SH/,QG
M8Q(#*2,XW*,X.,X-?N+#"EO$D42+'&@"JB# 4#H .PKQW]L;PW9>*/V8_B):
MWT2R)!I4M[$67)26']ZC#T.Y!^!-?)T<]KU,1%22Y6[6/H:F4T8TFXM\R1^&
M]?L[_P $_OBK?_%7]G#2)M5F-SJ6BSR:/+.WWI%C"M$6]_+= 3WVY[U^,5?J
M/_P29N)&^#_C*$L3$FNAU7T)MXP3_P".C\J]C/J:EA.9[IK_ "/-RF;CB.5;
M-'.?\%=/^0+\,O\ KXU#_P!!@K\Y=)U:\T'5;+4]/N)+._LYDN+>XB.'BD1@
MRLI[$$ _A7Z-?\%=/^0+\,O^OC4/_08*_-NM\FUP,/G^;,LS_P![E\OR/4/@
M_P# 'XA?M)^(-17POISZG+&WGW^I7DPCAC9VSEY&ZL22=HRQY., UZMXV_X)
MM_&3P7X=N]8%KH^NQ6L332VVDWK23A%&6*HZ)N. ?E4DGL":_1']B'X=P?#C
M]F7P5;)"L=UJEHNLW3*N"\EP!(I;W$9C7_@ KW:O Q.>UH5W&DERIV]3UZ.4
MTI4DZC?,S^=+IP>#7W+_ ,$K?BM?Z+\4-9\ RR[](UJT>^AB8_ZNZAQDK_O1
MEL^NQ?2OF[]JCPO:>#/VB_B%I%C"EO90ZQ.\,,8PL:2'S H'8 /@#VKT#_@G
M2S+^UUX- ) :*_!P>H^Q3'^E?2XWEQ&!G)K1QO\ A='AX7FHXN,5WM^A^MOQ
M8^(^F_"/X<^(/&&JG_0M)M6G,><&5^D<8/JSE5'NU?A;\6/BIX@^,WCK4_%7
MB2[:ZU"\D)6/<?+MX\G;%&#]U%' 'XG))-?I3_P56\5/I/P+T'18I61M6UI/
M,0'&^.*-W.?7#F,U^4]>5D&&C&BZ[6LOR7_!/0S>M*5145LOS/0_@S\ ?&_Q
M\UR?3/!NCM?M;*'N;J5Q%;VZDX&^1N 3V49)P<#@U[1XH_X)H_&GPWH\U_#9
MZ/KAAC,C6NEWQ><@#)"JZ)N/L"2>V:^_/V"?AS;_  [_ &8_">R-1>ZW$=9N
MY .7:;F//TB$:_@:^AJX,5GM:G7E&DERIV]3KP^54I4E*HW=G\ZUS;36=Q+;
MW$3P3Q.8Y(I%*LC X*D'D$'M7Z"?\$S_ -J"]CUI?A)XDO7N+&XC>3099CDP
MR*"SV^?[I4,RCL5(_B KR;_@I?X!M/!?[2DU[8VT=M!X@TV'5)%B4*IF+R12
M-@=V,08GN6)ZDU\Y?#GQ9=^ _'_ASQ%82&.[TO4(+N,@XR4D#8/L0"".X)KZ
M.I"&9X.[7Q*Z\F>+3E+ XJU]G9^:/V:_;>_Y-3^(W_8/7_T='7XAU^W'[:TR
MW/[)GQ"F3E)--1U^AEC(K\1Z\SA[_=Y_XOT1WYS_ !8^GZGZH_\ !)W_ )(;
MXK_[&.3_ -);>OMROB/_ ()._P#)#?%?_8QR?^DMO7VY7RN:?[[4]3WL#_NT
M/0_-O_@KK_R&_AC_ ->^H?\ H5O7Y[5^A/\ P5U_Y#?PQ_Z]]0_]"MZ_/:ON
M\G_W&G\_S9\IF7^]S^7Y(_H2\#_\B7H'_8/M_P#T6M?B)^UA_P G+_$W_L/W
M?_HPU^W?@?\ Y$O0/^P?;_\ HM:_$3]K#_DY?XF_]A^[_P#1AKYW(/\ >:GI
M^I[6<?P(>OZ'G-CXDU32](U/2[._N+;3M3$8O;:)RJ7 C;<@<=P&Y /?![5[
M]\*_^"?_ ,7?BQX:M=?L]-L=$TR[3S+:36[DP/,G9PBJS!3V) R,$<$&O/OV
M9/ -K\4/C[X'\-7\?G:=>:E&UU$<XDACS)(G']Y4(_&OW=CC2&-8XU"(H"JJ
MC  '0"O5S;,IX%QA12YGJSSLOP4<4G.H]%H?AK\>/V4?B%^SJEG<>*]/MWTR
M\<Q0ZGITWG6YD SL)(!5B,D!@,X.,X->/9QR.#7[;?MS:#;>(/V5?'\=RH/V
M:S6\B;&2LD4J."/R(_$U^)-=F5XV>.H.=1:IV.;,,+'"U5&&S1^U'[!_Q<N?
MB_\ LY:'>:C<R7>L:1))H][/*VYY'B"E&)/))B>(DGJ<UQ'_  44_:7N_@S\
M/K7PMX<NWM/%/B17'VJ+A[2S7B1U/9V)V*>PWD8(%<O_ ,$F9&/P<\8IGY1K
MV0/<V\6?Y"OE'_@HUXRN/%?[5'B*TD<M:Z';VVFVRXQA1$LK_P#D263\,5\[
MA\%"IFLX->[&[M_7FSVJV)G# 1G?5V7]?<?,A)8DGDU[W\&?V(?BI\<= CUW
M1-*MM.T28D07^L3FW2?'5D4*S,O^T%QP<'BO-?@WX+C^(WQ8\(>&)MWD:MJM
MO:3;.&\MY '(/;Y<\U^^6EZ9::+IMKI]A;QVEC:Q+!!;Q+M2.-0 J@=@  *]
MK-LRG@>6%)>\^_8\O+\#'%7E4>B/QW\:?\$Y_C;X-T^:\CT*S\0PPJ6==%O%
MFDP/[L;!78^R@GVKZ6_X)<? O5?",?C#QOX@TZXTN^F8:+:VMY T,Z*I629F
M5@" 6\H#W1J^_**^7KYS7Q%"5&:6O5'O4<MHT:JJP;T/S\_X*<?M+7GA^WMO
MA3X<O)+6>^@%SKLT7!\ALB.W!]&Y9O8(,X9A7YNZ?I]UJVH6UC96\EW>7,JP
MP6\*EGD=B JJ!R220 *])_:B\:7/Q _:&^(&LW,GF;M8N+:'VAA<PQ#_ +XC
M7\<U;_93^('A?X5_'3P[XL\7I<R:/I9EFVVL F?SO+98R%)'1F!SVQ7V>#H_
M4L&E"-Y6OZNW](^9Q-7ZUB7S.RO;T1]-_#S_ ()/>(-:\.PWOB[QG;^'-3F7
M=_9MG9?:_)R. \GF(-WJ%!'^T:^?_P!I[]D'Q;^S'?6LVI3PZWX<OI&BM-9M
M(V12P&=DJ'/EN1D@98$ X)P<??G_  ]"^#'IXB_\%R__ !RO)/VK/VX_A%\=
M/@7XC\):<FM_VO<B*:Q>YL%5$FCE5QD[SC*AESCHQKQL+BLT]NO;0?*WKIM_
MPQZ=?#X#V3]G)<R\]SXB^"7QBUWX%_$;2_%F@SM'-;.%N;?/R75N2/,A<>C
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M4,_Y/!\?_P#</_\ 3?;5^T5?B[_P4,_Y/!\?_P#</_\ 3?;5Y/#W^]2_PO\
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M'[F-)K>6.1%DC="K*PR"".01Z5CF.93P<U2HQ2UN:X/ QQ$74JRN?SK5^_\
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M]O+BY>2:XN-*@DDD8GEF8IDD^IK@R6M[&K-VOI^IV9G2]M3BKVU/SZ_X)O\
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+U[E99AN=N=^A_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
